摘要
目的分析比较盐酸哌罗匹隆与利培酮治疗首发精神分裂症的效果及安全性。方法240例首发精神分裂症患者为研究对象,依据治疗方案不同分为对照组与观察组,各120例。观察组患者采用盐酸哌罗匹隆治疗,对照组患者采用利培酮口腔崩解片治疗。对比两组治疗效果、治疗后阳性与阴性症状量表(PANSS)评分及治疗期间不良反应发生情况。结果观察组治疗总有效率91.67%高于对照组的78.33%,差异有统计学意义(P<0.05)。观察组PANSS总分(61.21±16.24)分、一般精神病理量表分(23.22±3.34)分、阳性量表分(17.22±4.33)分、阴性量表分(15.13±4.66)分均明显低于对照组的(88.02±16.25)、(26.56±8.31)、(24.28±4.55)、(20.32±6.88)分,差异有统计学意义(P<0.05)。观察组不良反应发生率2.50%低于对照组的12.50%,差异有统计学意义(P<0.05)。结论首发精神分裂症患者应用盐酸哌罗匹隆治疗疾病的效果较好,安全性强、可改善患者的阴性症状及阳性症状,值得进一步在临床内推广及应用。
Objective To analyze and compare the effect and safety between perospirone hydrochloride and risperidone in the treatment of first-episode schizophrenia.Methods A total of 240 patients with firstepisode schizophrenia were selected as the research subjects,and the patients were divided into the control group and the observation group according to different treatment schemes,with 120 cases in each group.Patients in the observation group were treated with perorpirone hydrochloride,and patients in the control group were treated with risperidone orally disintegrating tablets.The therapeutic effect,positive and negative symptom scale(PANSS)scores after treatment,and the occurrence of adverse reactions during treatment were compared between the two groups.Results The total effective rate 91.67% of the observation group was higher than 78.33% of the control group,and the difference was statistically significant(P<0.05).The total score of PANSS(61.21±16.24)points,general psychopathological scale score(23.22±3.34)points,positive scale score(17.22±4.33)points and negative scale score(15.13±4.66)points in observation group were significantly lower than(88.02±16.25),(26.56±8.31),(24.28±4.55),and(20.32±6.88)points in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 2.50%,which was lower than 12.50% in the control group,and the difference was statistically significant(P<0.05).Conclusion Perospirone hydrochloride has a good effect and high safety for patients with first-episode schizophrenia,and can improve the negative and positive symptoms of patients,which is worthy of further clinical promotion and application.
作者
岳佳
YUE Jia(Shenyang Mental Health Center,Shenyang 110168,China)
出处
《中国现代药物应用》
2022年第12期130-133,共4页
Chinese Journal of Modern Drug Application
关键词
盐酸哌罗匹隆
利培酮
首发精神分裂症
阳性与阴性症状量表
安全性
Perospirone hydrochloride
Risperidone
First-episode schizophrenia
Positive and negative syndrome scale
Safety
